Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAPPHIRE: Verinurad and Allopurinol in CKD and Hyperuricaemia
NCT03990363Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2019
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 2, randomised, double-blind trial of verinurad in chronic kidney disease (CKD) and hyperuricemia (5 arms), sponsored by AstraZeneca. Primary endpoint: Urinary Albumin to Creatinine Ratio Change From Baseline at 6 months. Started Jul 2019; status: completed.
02
Drugs
verinurad
03
Conditions
chronic kidney disease (CKD)hyperuricemia
Beyond the preview
Go deeper on NCT03990363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03990363.